Year All 2026 2025 2024 2023 Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress September 4, 2026 Read more Rein Therapeutics to Present at Upcoming September Investor Conferences September 3, 2026 Read more Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis August 20, 2026 Read more Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update August 14, 2026 Read more Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications August 4, 2026 Read more Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries July 21, 2026 Read more Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom June 11, 2026 Read more Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option May 18, 2026 Read more Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock April 30, 2026 Read more Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis April 29, 2026 Read more
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress September 4, 2026 Read more
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis August 20, 2026 Read more
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update August 14, 2026 Read more
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications August 4, 2026 Read more
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries July 21, 2026 Read more
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option May 18, 2026 Read more
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock April 30, 2026 Read more
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis April 29, 2026 Read more
